Supplemental Oxygen in Pulmonary Fibrosis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

19 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-10-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To enhance understanding of supplemental oxygen-its utility in and adoption by patients with pulmonary fibrosis-by examining how patients perceive it and by determining how perceptions and patient-centered outcome measures change from before to after supplemental oxygen is prescribed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Short-term Effects of Supplemental Oxygen in Patients With IPF

NCT03050255

Idiopathic Pulmonary Fibrosis (IPF)

COMPLETED NA

Effect of Supplemental Oxygen on Maximal Oxygen Consumption in Patients With Chronic Obstructive Pulmonary Disease

NCT01294033

Chronic Obstructive Pulmonary Disease

COMPLETED NA

Acute Effects of Oxygen Supplementation Among IPF Patients

NCT03688334

Idiopathic Pulmonary Fibrosis

UNKNOWN NA

Portable Oxygen Concentrator Improvements to Physical Activity, Oxygen Usage, and Quality of Life in Chronic Obstructive Pulmonary Disease Patients Using Long-term Oxygen Therapy (POC-STEP)

NCT03513068

COPD

TERMINATED NA

Effect of Ambulatory Oxygen on the Walking Test in Patients With Pulmonary Fibrosis

NCT02668029

Pulmonary Fibrosis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators aim to recruit patients with PF to participate in interviews and/or a one-year study of supplemental oxygen (O2). In the one-year study, the investigators will collect data before and for one year after PF patients are prescribed daily-use supplemental oxygen and compare outcomes, including shortness of breath, quality of life, fatigue, cough, and day-to-day functioning before and after O2.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pulmonary fibrosis patients

Patients with pulmonary fibrosis of any cause (idiopathic, connective tissue disease, chronic hypersensitivity pneumonitis)

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patient-Participants

(Using daily 02 therapy at time of enrollment)

* Diagnosis of PF
* Able to read and speak English
* Has been on daily-use supplemental oxygen for more than one year

(Not using daily 02 therapy at time of enrollment)

* Diagnosis of PF
* Able to read, speak and write in English
* Has not been prescribed daily-use supplemental oxygen
* Forced vital capacity \<75% and diffusing capacity \<65% of predicted values
* Subject's physician allows the subject to abstain from daily-use supplemental oxygen for 7-10 days after prescription to allow data for collection

Primary Supporters

* Self-report status of providing care or support to a person living with pulmonary fibrosis who has used supplemental oxygen for more than one year
* Able to speak English

O2 Prescribers

* Self-report status of being a prescriber of daily-use supplemental oxygen to PF patients
* Able to speak English

O2 Prescribers

Exclusion Criteria

Patient-Participants (Using daily 02 therapy at time of enrollment)

* No diagnosis of PF
* Unable to read and speak English
* Has been on daily-use supplemental oxygen for less than one year

(Not using daily 02 therapy at time of enrollment)

* No diagnosis of PF
* Unable to read, speak and write in English
* Using supplemental oxygen during the day
* Subject's physician does not allow the subject to abstain from daily-use supplemental oxygen for 7-10 days after prescription to allow data for collection

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes